Information Provided By:
Fly News Breaks for November 29, 2018
MYL, AGRX
Nov 29, 2018 | 07:47 EDT
Maxim analyst Caroline Palomeque initiated Agile Therapeutics (AGRX) with a Buy rating and a price target of $3, saying that she likes the risk-reward on the stock as the company approaches an NDA resubmission for its Twirla - a low-dose combined hormone contraceptive transdermal patch. The analyst cites the large potential market opportunity for the product, with combined hormone contraceptive market generating about $4B and the current patch availability being limited to Mylan's (MYL) Xulane. Palomeque further contends that Twirla "offers a low-dose, safer estradiol, potentially with no 'black box' warning."